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     ABSTRACT 
 
BACKGROUND: 
 The advent of ancillary test like immunohistochemistry is becoming very 
useful in discriminating benign from malignant thyroid neoplasms. Galectin-3 is 
a marker implicated in the regulation of cellular proliferation, apoptosis, 
malignant transformation and metastasis of tumor cells. CD56 is expressed in 
normal thyroid follicular cells and its absence of expression is found to be 
associated with malignancy. 
 
AIMS: 
 To study the immunohistochemical expression of Galectin-3 and CD56 in 
thyroid neoplasms and to evaluate the usefulness of combining these 
immunohistochemical markers in differentiating malignant from benign thyroid 
tumors. 
 
MATERIALS AND METHODS: 
 In this prospective study, we evaluated the expression of two 
immunohistochemical markers - Galectin-3 and CD56 in 30 cases of thyroid 
neoplasms. The benign neoplasms included follicular adenoma (n=7) and 
Hurthle cell adenoma (n=1). The malignant neoplasms included papillary 
thyroid carcinoma (classical type) (n=14), papillary carcinoma-follicular variant 
(n=4) and follicular carcinoma (n=4). 
 
RESULTS: 
In this study, there was 100% diffuse and strong positive expression of 
Galectin-3 in all the 14 cases of papillary carcinoma (classical type), favouring 
it to be a marker for detection of papillary carcinoma. Among the 4 cases of 
follicular variant of papillary carcinoma, 3 cases (75%) showed galectin-3 
positivity. Absence of CD56 membrane staining was noted in 13 out of the 14 
cases (92.9%) of papillary carcinoma (classical type) and also 3 out of 4 cases 
(75%) of follicular variant of papillary carcinoma and 2 out of 4 cases of 
follicular carcinoma showed negative CD56 expression.  
 
Galectin-3 in our study showed 100% negativity in follicular adenoma            
(7 out of 7 cases). All the benign cases (7 cases of follicular adenoma and 1 case 
of Hurthle cell adenoma) (100%) showed positive staining with CD56, 
supporting it to be a marker for benignity. 
 
CONCLUSION: 
Galectin-3 is found to be a good marker of malignancy, especially in the 
diagnosis of papillary thyroid carcinoma. CD56 is considered a good negative 
diagnostic marker for papillary thyroid carcinoma. CD56 is found to be a better 
marker to indicate the benign nature of the tumor. Absence of CD56 expression 
is useful for differentiating follicular variant of papillary carcinoma from benign 
follicular thyroid lesion like follicular adenoma. This combined panel of 
markers - galectin-3 and CD56 was very useful in discriminating malignant 
from benign thyroid neoplasms, especially, in tumors with equivocal 
morphological features like follicular variant of papillary carcinoma from 
follicular adenoma. 
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